ストックスクリーナーアプリを入手
8.94
7.07%
0.59
前日終値:
$8.35
開ける：
$8.95
24時間の取引高:
412
Relative Volume:
0.03
時価総額：
$76.55M
収益：
-
当期純損益:
$-53.45M
株価収益率:
-0.4118
EPS:
-21.71
ネットキャッシュフロー:
$-31.81M
1週間 パフォーマンス:
-10.51%
1か月 パフォーマンス:
+16.86%
6か月 パフォーマンス:
-35.68%
1年 パフォーマンス:
-10.06%
1日の値動き範囲:
$8.95
$8.95
1週間の範囲:
$8.00
$9.95
52週間の値動き範囲:
$5.90
$18.17
Surrozen Inc Stock (SRZN) Company Profile
名前
Surrozen Inc
セクター
電話
650-475-2820
住所
171 OYSTER POINT BLVD, SOUTH SAN FRANCISCO
SRZN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SRZN
Surrozen Inc
|
8.95 | 76.55M | 0 | -53.45M | -31.81M | -21.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.70 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.62 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.04 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
559.57 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
239.92 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Surrozen Inc Stock (SRZN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-30 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-10-11 | 開始されました | BofA Securities | Buy |
| 2021-09-15 | 開始されました | Guggenheim | Buy |
| 2021-09-07 | 開始されました | Stifel | Buy |
Surrozen Inc (SRZN) 最新ニュース
Surrozen (SRZN) Files for $150 Million Mixed Securities Offering - GuruFocus
Surrozen (SRZN) Files for $150 Million Mixed Securities Offering | SRZN Stock News - GuruFocus
Surrozen Inc Files For Mixed Shelf Of Up To $150 MillionSEC Filing - marketscreener.com
(SRZN) Proactive Strategies - news.stocktradersdaily.com
Down -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a Turnaround - Yahoo Finance
Surrozen Holds Successful 2025 Annual Stockholders Meeting - TipRanks
Surrozen secures patent for tissue repair technology By Investing.com - Investing.com Nigeria
Surrozen granted patent from USPTO directed to antibody-based molecules - TipRanks
Surrozen (SRZN) Secures New U.S. Patent for Innovative SWAPTM Te - GuruFocus
Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway - The Manila Times
Surrozen secures patent for tissue repair technology - Investing.com
Breakthrough Patent: Surrozen's New Wnt Technology Could Transform Tissue Repair Therapeutics - Stock Titan
Surrozen’s (SRZN) Buy Rating Reaffirmed at HC Wainwright - Defense World
Surrozen (SRZN) Receives Continued "Buy" Rating from HC Wainwright | SRZN Stock News - GuruFocus
Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Surrozen, Inc. Reports Q1 2025 Financial Results - TipRanks
Surrozen, Inc. Reports First Quarter 2025 Financial Results and Business Update Focused on Ophthalmology Pipeline - Nasdaq
CyberCatch Announces Cybersecurity Solution To Protect Thousands of Drinking Water Systems in U.S. that EPA OIG Report Reveals are at Risk of Cyber Attack with One-Day Disruption Cost of $43.5 Billion - The Globe and Mail
BestGrowthStocks.Com Issues a Comprehensive Analysis of Richtech Robotics - The Globe and Mail
Surrozen’s SZN-8141 ameliorates retinopathy in murine models - BioWorld MedTech
Trend Tracker for (SRZN) - news.stocktradersdaily.com
Surrozen files to sell 5.21M shares of common stock for holders - MSN
When (SRZN) Moves Investors should Listen - news.stocktradersdaily.com
Finance Watch: As Stocks Tumble, Offerings Slow, Financial Alternatives Rise - insights.citeline.com
Surrozen’s Strategic Shift to Ophthalmology and Wnt Pathway Innovations Justify Buy Rating - TipRanks
Insiders Are Loving These 5 Tech and Biotech Stocks - 24/7 Wall St.
Surrozen (SRZN) to Release Earnings on Wednesday - Defense World
Surrozen Focuses on Ophthalmology Amid Financial Challenges - TipRanks
Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates - The Manila Times
Surrozen Lands Massive $175M Deal: What This Means for Its Eye Disease Pipeline - Stock Titan
Friday’s Insider Moves: Major Buys in Insurance and Biotech, Sells in Energy - Investing.com Australia
Surrozen sees $11.9 million in stock purchases by Column Group - Investing.com UK
Surrozen Secures $76.4M in Private Placement Deal - TipRanks
Surrozen drops hepatitis drug after Phase I flop - Yahoo
Surrozen shifts focus to eye disease treatments, secures $175M funding - Investing.com India
Surrozen Secures $175Mln In Oversubscribed Private Placement To Advance Ophthalmology Pipeline - Nasdaq
Surrozen to Raise Up to $175 Million in Private Placement; Fine-Tunes Ophthalmology Clinical Programs - MarketScreener
Surrozen raises $175M, to focus on ophthalmology; CBC Group has a new $1B fund - Endpoints News
Surrozen shifts focus to eye disease treatments, secures $175M funding By Investing.com - Investing.com South Africa
Surrozen, Inc. Prioritizes Ophthalmology Pipeline with $175 Million Financing and Discontinues SZN-043 Development - Nasdaq
Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases - The Manila Times
Major Pivot: Surrozen Lands $175M to Develop Breakthrough Eye Disease Treatments - Stock Titan
(SRZN) Trading Advice - Stock Traders Daily
Reviewing Surrozen (NASDAQ:SRZN) & Tenaya Therapeutics (NASDAQ:TNYA) - Defense World
Wnt efforts condensing at Dewpoint, Surrozen, more - BioWorld MedTech
(SRZN) On The My Stocks Page - Stock Traders Daily
Week Ahead (Sep.13- 17): FDA Decision, Data Readouts (CALT, ASLN, LIFE…) - RTTNews
Better Warren Buffett Stock: Nu Holdings vs. Bank of America - The Globe and Mail
(SRZN) Trading Signals - Stock Traders Daily
H.C. Wainwright sets $32 target on Surrozen stock with Buy rating - MSN
MicroStrategy Is Rebranding to ‘Strategy.’ Should You Buy, Sell, or Hold MSTR Stock? - The Globe and Mail
Surrozen Inc (SRZN) 財務データ
収益
当期純利益
現金流量
EPS
Surrozen Inc (SRZN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Li Yang | Exec. Vice President, Research |
Jan 03 '25 |
Sale |
17.37 |
843 |
14,643 |
13,345 |
| Williams Charles O | CFO and COO |
Jan 03 '25 |
Sale |
17.37 |
1,181 |
20,514 |
8,982 |
1.37%
0.65%
大文字化:
|
ボリューム (24 時間):